Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin

Anticancer drugs that target cellular antioxidant systems have recently attracted much attention. Auranofin (AF) is currently evaluated in several clinical trials as an anticancer agent that targets the cytosolic and mitochondrial forms of the selenoprotein thioredoxin reductase, TXNRD1 and TXNRD2....

Full description

Saved in:
Bibliographic Details
Main Authors: Pierre Sabatier, Christian M. Beusch, Radosveta Gencheva, Qing Cheng, Roman Zubarev, Elias S.J. Arnér
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
Online Access:https://doaj.org/article/2416c4c7c36649e9989635fa4100678e
Tags: Add Tag
No Tags, Be the first to tag this record!